5-苯基-1,3,4-噻二唑衍生物的合成及含SH2结构域蛋白酪氨酸磷酸酶1 (SHP1)抑制活性研究

doi:10.6023/cjoc202104041

有机化学 ›› 2021, Vol. 41 ›› Issue (8): 3097-3105.DOI: 10.6023/cjoc202104041 上一篇下一篇

研究论文

5-苯基-1,3,4-噻二唑衍生物的合成及含SH2结构域蛋白酪氨酸磷酸酶1 (SHP1)抑制活性研究

于丽杰^a, 冯勃^b^,^c, 王智佳^a, 高立信^a^,^b, 张纯^a^,^d, Rajendran Satheeshkumar^a, 李佳^b, 周宇波^b^,^c^,^*(), 王文龙^a^,^*()

a 江南大学药学院江苏无锡 214122
b 中国科学院上海药物研究所国家新药筛选中心上海 201203
c 中国科学院药物创新研究院中山研究院广东中山 528400
d 南京大学化学化工学院南京 210023

收稿日期:2021-04-18 修回日期:2021-05-19 发布日期:2021-06-02
通讯作者: 周宇波, 王文龙
作者简介:
† 共同第一作者
基金资助:
国家自然科学基金(21772068); 国家自然科学基金(81773779); 江苏省研究生科研与实践创新计划(KYCX20-1965); 江苏省自然科学基金(BK20190608)

Synthesis of 5-Phenyl-1,3,4-thiadiazole Derivatives and Their Biochemical Evaluation against Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 1 (SHP1)

Lijie Yu^a, Bo Feng^b^,^c, Zhijia Wang^a, Lixin Gao^a^,^b, Chun Zhang^a^,^d, Rajendran Satheeshkumar^a, Jia Li^b, Yubo Zhou^b^,^c(), Wenlong Wang^a()

a School of Pharmaceutical Sciences, Jiangnan University, Wuxi, Jiangsu 214122
b National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203
c Zhongshan Institute for Drug Discovery, Institutes of Drug Discovery and Development, Chinese Academy of Sciences, Zhongshan, Guangdong 528400
d School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023

Received:2021-04-18 Revised:2021-05-19 Published:2021-06-02
Contact: Yubo Zhou, Wenlong Wang
About author:
† (These authors contributed equally to this work).
Supported by:
National Natural Science Foundation of China(21772068); National Natural Science Foundation of China(81773779); Postgraduate Research & Practice Innovation Program of Jiangsu Province(KYCX20-1965); Natural Science Foundation of Jiangsu Province(BK20190608)

文章分享

1. 213097S.pdf(6099KB)

摘要/Abstract

作为细胞信号转导通路的关键节点分子, 含SH2结构域蛋白酪氨酸磷酸酶1 (SHP1)是潜在的抗肿瘤靶点. 已知的SHP1抑制剂屈指可数. 设计并合成了11个5-苯基-1,3,4-噻二唑衍生物. 活性测试结果表明, 部分衍生物对SHP1显示了一定强度的抑制活性. 其中, 化合物5b [IC₅₀=(1.33±0.16) μmol/L]对SHP1显示了中等强度的抑制活性, 对PTP1B和TCPTP不显示抑制活性, 对SHP2显示了2倍的选择性, 为发现新型SHP1抑制剂提供了新的骨架类型.

关键词: 5-苯基-1,3,4-噻二唑衍生物, 含SH2结构域蛋白酪氨酸磷酸酶1 (SHP1), 抑制剂, 构效关系

The Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP1) is a convergent node for oncogenic cell-signaling cascades. Consequently, SHP1 represents a potential target for drug development in cancer treatment. Meanwhile only countable SHP1 inhibitors have been reported. A new type of SHP1 inhibitors with 5-phenyl-1,3,4-thiadiazole scaffold was developed. The representative compound 5b exhibited SHP1 inhibitory activity with IC₅₀ of (1.33±0.16) μmol/L, exhibited about 2-fold selectivity for SHP1 over SHP2, and had no detectable activity against PTP1B and TCPTP, and offered a novel scaffold to develop new SHP1 inhibitors.

Key words: 5-phenyl-1,3,4-thiadiazole derivatives, Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP1), inhibitors, structure-activity relationships

引用此文

于丽杰, 冯勃, 王智佳, 高立信, 张纯, Rajendran Satheeshkumar, 李佳, 周宇波, 王文龙. 5-苯基-1,3,4-噻二唑衍生物的合成及含SH2结构域蛋白酪氨酸磷酸酶1 (SHP1)抑制活性研究[J]. 有机化学, 2021, 41(8): 3097-3105.

Lijie Yu, Bo Feng, Zhijia Wang, Lixin Gao, Chun Zhang, Rajendran Satheeshkumar, Jia Li, Yubo Zhou, Wenlong Wang. Synthesis of 5-Phenyl-1,3,4-thiadiazole Derivatives and Their Biochemical Evaluation against Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 1 (SHP1)[J]. Chinese Journal of Organic Chemistry, 2021, 41(8): 3097-3105.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

图/表 7

Figure 1. Chemical structures of reported SHP1 inhibitors

Figure 2. Structures of modulators of PTPs

Compd.	R¹	R²	R³	SHP1
Compd.	R¹	R²	R³	Inhibition/% at 50 μmol/L	IC₅₀/(μmol•L^–1)
2a	3-NO₂	4-NHMe	NH₂	27.5±19.1	—
2b	3-NO₂		NH₂	20.9±16.9	—
2c	3-NO₂	4-OMe	NH₂	21.6±5.1	—
2d	3-OMe	4-OMe	NH₂	–2.4±7.2	—
2e	3-OH	3-OH	NH₂	8.6±1.8	—
4	3-NO₂	4-NHMe		80.6±6.5	23.42±3.17
5a	3-NO₂	4-NHMe		64.3±11.0	4.40±1.09
5b	3-NO₂	4-NHMe		92.8±2.1	1.33±0.16
5c	3-NO₂	4-NHMe		69.7±2.7	21.56±2.61
5d	3-NO₂			36.4±8.4	—
5e	3-NO₂	4-OMe		38.6±39.4	—
NSC-87877	—	—	—	—	34.76±4.46

Table 1. SHP1 inhibitory activities of compounds 2a~2e, 4 and 5a~5e

Scheme 1. Synthetic route of compounds 2a~2e, 4 and 5a~5e Reagents and conditions: (a) thiosemicarbazide, POCl3, 80 ℃, 2.5 h, 48%~90%; (b) 3-((tert-butoxycarbonyl)amino)benzoic acid, HATU, DIPEA, DMF, r.t., overnight, 40%; (c) HCl-dioxane, r.t., overnight, 90%; (d) furan-2-carboxylic acid (5-methylfuran-2-carboxylic acid, tetrahydrofuran-2-carboxylic acid) HATU, DIPEA, DMF, r.t., overnight, 64%~68%; (e) 3-(furan-2-carboxamido)benzoic acid, HATU, DIPEA, DMF, r.t., overnight, 49%; (f) 3-(furan-2-carboxamido)benzoic acid, HATU, DIPEA, DMF, r.t., overnight, 26%.

Compd.	SHP1	SHP2	SHP2/SHP1	PTP1B	TCPTP
5b	1.33±0.16	2.99±0.36	2.25	NA^b	NA^b
NSC-87877	34.76±4.46	33.71±0.72		50.04±11.91	40.70±6.50

Table 2. IC50a (μmol•L–1) values of compound 5b against PTPs

Figure 3. Characterization of 5b to SHP1 (A) Time-independent inhibition of SHP1 by 5b; (B) typical competitive inhibition of 5b shown by Lineweaver-Burk plot; (C) the initial velocity determined with various concentrations of 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) at various fixed concentrations of 5b

Figure 4. Calculated results of molecular properties for 5b and docking simulation (A) Molecular electrostatic properties of mapped on the 0.001 a.u. contour of the electronic density at the DFT//B3LYP/6-31G(d) level; (B) docking pose of 5b with SHP1 (PDB Entry: 1FPR): relative position of 5b and WPD_loop (orange), Q_loop (purple), P_loop (Yellow) and PTyr_loop (green) in SHP1; (C) strong interactions between 5b and the nearest residues

参考文献 37

[1]	Tonks, N. K. FEBS J. 2013, 280, 346.
[2]	Hendriks, W.; Elson, A.; Harroch, S.; Pulido, R.; Stoker, A.; Hertog, J. D. FEBS J. 2013, 280, 708. doi: 10.1111/febs.12000 pmid: 22938156
[3]	Frankson, R.; Yu, Z. H.; Bai, Y.; Li, Q.; Zhang, R. Y.; Zhang, Z. Y. Cancer Res. 2017, 77, 5701. doi: 10.1158/0008-5472.CAN-17-1510
[4]	Varone, A.; Spano, D.; Corda, D. Front. Oncol. 2020, 10, 935. doi: 10.3389/fonc.2020.00935
[5]	Sandur, S. K.; Pandey, M. K.; Sung, B.; Aggarwal, B. B. Mol. Cancer Res. 2010, 8, 107. doi: 10.1158/1541-7786.MCR-09-0257
[6]	Sharma, Y.; Bashir, S.; Bhardwaj, P.; Ahmad, A.; Khan, F. Immunol. Res. 2016, 64, 804. doi: 10.1007/s12026-016-8805-y pmid: 27216862
[7]	Yuan, X.; Bu, H.; Zhou, J.; Yang, C. Y.; Zhang, H. J. Med. Chem. 2020, 63, 11368 doi: 10.1021/acs.jmedchem.0c00249
[8]	Dempke, W. M.; Peter, U.; Klaus, F.; Timothy, C. Oncology 2018, 95, 1.
[9]	Song, M.; Park, J. E.; Park, S. G.; Lee, D. H.; Choi, H. K.; Park, B. C. Biochem. Biophys. Res. Commun. 2009, 381, 491. doi: 10.1016/j.bbrc.2009.02.069
[10]	Kundu, S.; Fan, K.; Cao, M.; Lindner, D. J.; Zhao, Z. J.; Borden, E.; Yi, T. L. J. Immunol. 2010, 184, 6529. doi: 10.4049/jimmunol.0903562
[11]	Arabaci, G.; Yi, T.; Fu, H.; Porter, M. E.; Beebe, K. D.; Pei, D. Bioorg. Med. Chem. Lett. 2002, 12, 3047. pmid: 12372498
[12]	Yi, T.; Elson, P.; Mitsuhashi, M.; Jacobs, B.; Hollovary, E.; Budd, G. T.; Spiro, T.; Triozzi, E.; Borden, E. C. Oncotarget 2011, 2, 1155. doi: 10.18632/oncotarget.v2i12
[13]	Lu, L.; Wang, S.; Zhu, M.; Liu, Z.; Guo, M.; Xing, S.; Fu, X. Biometals 2010, 23, 1139. doi: 10.1007/s10534-010-9363-8
[14]	Wang, Q.; Zhu, M.; Lu, L.; Yuan, C.; Fu, X. Dalton. Trans. 2011, 40, 12926. doi: 10.1039/c1dt11006c
[15]	Akiba, H.; Sumaoka, J.; Hamakubo, T.; Komiyama, M. Anal. Bioanal. Chem. 2014, 406, 2957. doi: 10.1007/s00216-014-7707-x
[16]	Frija, L.; Pombeiro, A.; Kopylovich, M. N. Eur. J. Org. Chem. 2017, 19, 2670.
[17]	Yang, H.; Li, C. Y.; Wang, X. M.; Yang, Y. H.; Zhu, H. L. Chem. Rev. 2014. 45, 5572.
[18]	Wang, W. L.; Yang, D. L.; Gao, L. X.; Tang, C. L.; Ma, W. P.; Ye, H. H.; Zhang, S. Q.; Zhao, Y. N.; Xu, H. J.; Hu, Z.; Chen, X.; Fan, W. H.; Chen, H. J.; Li, J. Y.; Nan, F. J.; Li, J.; Feng, B. N. Molecules 2013, 19, 102. doi: 10.3390/molecules19010102
[19]	Wang, W.L; Chen, X.; Gao, L.X; Sheng, L.; Li, J. Y.; Li, J.; Feng, B. N. Chem. Biol. Drug Des. 2015, 86, 1161. doi: 10.1111/cbdd.12587
[20]	Satheeshkumar, R.; Zhu, R.; Feng, B.; Huang, C.; Gao, Y.; Gao, L. X.; Shen, C.; Hou, T. J.; Xu, L.; Li, J.; Zhu, Y. L.; Zhou, Y. B.; Wang, W. L. Bioorg. Med. Chem. Lett. 2020, 30, 127170. doi: S0960-894X(20)30267-5 pmid: 32273218
[21]	Wang, W. L.; Chen, X. Y.; Gao, Y.; Gao, L. X.; Sheng, L.; Zhu, J. Y.; Xu, L.; Ding, Z. Z.; Zhang, C.; Li, J. Y.; Li, J.; Zhou, Y. B. Bioorg. Med. Chem. Lett. 2017, 27, 5154. doi: 10.1016/j.bmcl.2017.10.059
[22]	Wang, W. L.; Huang, C.; Gao, L. X.; Tang, C. L.; Wang, J. Q.; Wu, M. C.; Sheng, L.; Chen, H. J.; Nan, F. J.; Li, J. Y.; Feng, B. N. Bioorg. Med. Chem. Lett. 2014, 24, 1889.
[23]	Wang, W. L.; Luo, H.; Gao, Y.; Gao, L. X.; Sheng, L.; Zhou, Y. B.; Li, J. Y.; Li, J.; Feng, B. N. Chin. J. Org. Chem. 2016, 36, 2142. (in Chinese) doi: 10.6023/cjoc201603045
	(王文龙, 骆欢, 高雅, 高立信, 盛丽, 周宇波, 李佳, 李静雅, 冯柏年, 有机化学, 2016, 36, 2142.) doi: 10.6023/cjoc201603045
[24]	Pac, A.; As, A.; Fal, A.; Mb, B.; Mfe, C. J. Mol. Struct. 2019, 1179, 11. doi: 10.1016/j.molstruc.2018.10.082
[25]	Chen, Y. N.; LaMarche, M. J.; Chan, H. M.; Fekkes, P.; Garcia, F. J.; Acker, M. G.; Antonakos, B.; Chen, C. H.; Chen, Z.; Cooke, V. G.; Dobson, J. R.; Deng, Z.; Fei, F.; Firestone, B.; Fodor, M.; Fridrich, C.; Gao, H.; Grunenfelder, D.; Hao, H. X.; Jacob, J.; Ho, S.; Hsiao, K.; Kang, Z. B.; Karki, R.; Kato, M.; Larrow, J.; LaBonte, L. R.; Lenoir, F.; Liu, G.; Liu, S.; Majumdar, D.; Meyer, M. J.; Palermo, M.; Perez, L.; Pu, M.; Price, E.; Quinn, C.; Shakya, S.; Shultz, M. D.; Slisz, J.; Venkatesan, K.; Wang, P.; Warmuth, M.; Williams, S.; Yang, G.; Yuan, J.; Zhang, J. H.; Zhu, P.; Ramsey, T.; Keen, N. J.; Sellers, W. R.; Stams, T.; Fortin, P. D. Nature 2016, 535, 148. doi: 10.1038/nature18621
[26]	Welte, S.; Baringhaus, K. H.; Schmider, W.; Müller, G.; Petry, S.; Tennagels, N. Anal. Biochem. 2005, 338, 32. doi: 10.1016/j.ab.2004.11.047
[27]	Krishnan, N.; Koveal, D.; Miller, D. H.; Xue, B.; Akshinthala, S. D.; Kragelj, J.; Jensen, M. R.; Gauss, C. M.; Page, R.; Blackledge, M.; Muthuswamy, S. K.; Peti, W.; Tonks, N. K. Nat. Chem. Biol. 2014, 10, 558. doi: 10.1038/nchembio.1528
[28]	Zhang, W.; Hong, D.; Zhou, Y.; Zhang, Y.; Shen, Q.; Li, J. Y.; Hu, L. H.; Li, J. Biochim. Biophys. Acta 2006, 1760, 1505. pmid: 16828971
[29]	McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. J. Med. Chem. 2003, 46, 4265. pmid: 13678405
[30]	Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, Revision D.01, Gaussian, Inc., Wallingford, CT, 2013.
[31]	Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. J. Comput. Chem. 2009, 30, 2785. doi: 10.1002/jcc.v30:16
[32]	Yang, J.; Cheng, Z. L.; Niu, T. Q.; Liang, X. S.; Zhao, Z. Z. J.; Zhou, G. W. J. Biol. Chem. 2000, 275, 4066. pmid: 10660565
[33]	Zhang, B.; Wang, K. B.; Wang, W.; Wang, X.; Liu, F.; Zhu, J. P.; Shi, J.; Li, L. Y.; Han, H.; Xu, K.; Qiao, H. Y.; Zhang, X.; Jiao, R. H.; Houk, K. N.; Liang, Y.; Tan, R. X.; Ge, H. M. Nature 2019, 568, 122. doi: 10.1038/s41586-019-1021-x
[34]	Daina, A.; Michielin, O.; Zoete, V. Sci. Rep. 2017, 7, 1. doi: 10.1038/s41598-016-0028-x
[35]	Vachala, S. D.; Bhargavi, B. J. Chem. Pharm. Res. 2014, 6, 377.
[36]	Guan, P.; Wan, Y. C.; Hou, X. B.; Wang, L; Xu, W. F.; Tang, W. P.; Fang, H. Bioorg. Med. Chem. 2014, 22, 5766.
[37]	Jakovljević, K.; Matić, I. Z.; Stanojković, T.; Krivokuća, A.; Marković, V.; Joksović, M. D.; Mihailović, N.; Nićiforović, M.; Joksović, L. Bioorg. Med. Chem. Lett. 2017, 27, 3709. doi: S0960-894X(17)30696-0 pmid: 28709826

5-苯基-1,3,4-噻二唑衍生物的合成及含SH2结构域蛋白酪氨酸磷酸酶1 (SHP1)抑制活性研究

Synthesis of 5-Phenyl-1,3,4-thiadiazole Derivatives and Their Biochemical Evaluation against Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 1 (SHP1)

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用此文

分享此文

图/表 7

参考文献 37

相关文章 15

编辑推荐

相关统计

本文评价

[1]	霍海波, 李桂霞, 王世军, 韩春, 师宝君, 李健. 新型γ-咔啉衍生物的合成及其抑菌活性研究[J]. 有机化学, 2024, 44(1): 204-215.
[2]	左鑫, 许诗诺, 陈忠洋, 鄢剑锋, 袁耀锋. 茂铁类单分子结电子传输性质的研究进展[J]. 有机化学, 2023, 43(7): 2313-2322.
[3]	何金燕, 田富云, 吴青青, 郑月明, 陈玉婷, 许海燕, 金正盛, 詹丽, 程新强, 顾跃玲, 高召兵, 赵桂龙. 基于[3.3.3]螺桨烷的电压门控钙离子通道α2δ亚基配体的合成和生物活性研究[J]. 有机化学, 2023, 43(6): 2226-2238.
[4]	钟玉梅, 邹小颖, 卓小丫, 王逸涵, 申佳奕, 郑绿茵, 郭维. 4-氧代-2-亚胺基噻唑烷-5-亚基乙酸乙酯类化合物的设计、合成及抗癌活性[J]. 有机化学, 2023, 43(4): 1452-1461.
[5]	刘兴周, 于明加, 梁建华. 原小檗碱骨架的合成及其抗炎活性研究进展[J]. 有机化学, 2023, 43(4): 1325-1340.
[6]	徐欢, 吴鸿飞, 张晓鸣, 路星星, 孙腾达, 亓悦, 林誉凡, 杨新玲, 张莉, 凌云. 含1,2,3,4-四氢异喹啉片段磺酰肼和酰肼类化合物的设计、合成及生物活性研究[J]. 有机化学, 2023, 43(2): 725-733.
[7]	高建飞, 李瞬依, 何玉龙, 李英霞, 王贺瑶, 黄二芳, 胡春. 作为FABP4/5抑制剂喹啉类化合物的设计合成与生物活性研究[J]. 有机化学, 2023, 43(2): 636-645.
[8]	张雨杉, 桓臻, 杨金东, 程津培. 氮杂环磷氢试剂的氢转移活性研究进展[J]. 有机化学, 2023, 43(11): 3806-3825.
[9]	孙昌兴, 张福豪, 张欢, 李鹏辉, 姜林. 新型2-(1-甲基-1H-吡唑-4-基)嘧啶-4-甲酰胺的设计、合成、杀菌活性及分子对接研究[J]. 有机化学, 2023, 43(1): 229-235.
[10]	梁光平, 王维, 朱绪秀, 梁光焰, 杨俊, 王道平. 新型齐多夫定与4-苯胺喹唑啉骨架拼接产物的合成及体外抗肿瘤活性[J]. 有机化学, 2022, 42(9): 2793-2805.
[11]	张蓉, 郜祥, 陈玲玲, 南发俊. 噻唑-噁唑串联杂环类RNA剪接抑制剂的发现及构效关系研究[J]. 有机化学, 2022, 42(9): 2925-2939.
[12]	葛天鹏, 杨彦辰, 李淳朴, 张剑, 柳红. 盘状结构域受体1 (DDR1)激酶抑制剂的研究进展[J]. 有机化学, 2022, 42(9): 2760-2773.
[13]	杨竣喆, 许子超, 李淳朴, 程远征, 柳红. 原肌球蛋白受体激酶(TRK)抑制剂的研究进展[J]. 有机化学, 2022, 42(7): 2055-2069.
[14]	王春霞, 胡晓东, 许斌, 曹春阳. 靶向新型冠状病毒SARS-CoV-2主蛋白酶的抗病毒药物研究进展[J]. 有机化学, 2022, 42(7): 1974-1999.
[15]	王长凯, 孙腾达, 张学博, 杨新玲, 路星星, 徐欢, 石发胜, 张莉, 凌云. 新型含氟吡唑酰肼类化合物的设计合成与生物活性研究[J]. 有机化学, 2022, 42(5): 1527-1536.